Breast Imaging

What Is the Right Initial Imaging for Breast Cancer Screening During Lactation?

·
What Is the Right Initial Imaging for Breast Cancer Screening During Lactation?

A 32-year-old high-risk patient, six months postpartum and exclusively breastfeeding, presents for her annual check-up. She is due for her screening mammogram but expresses concern about its safety and effectiveness while lactating. As her physician, you face the decision of whether to proceed with screening, postpone it, or choose an alternative modality. This common clinical question requires balancing the benefits of early cancer detection against the unique physiological challenges of the lactating breast. This article provides a detailed workflow for this specific scenario: initial imaging for breast cancer screening in a lactating woman. According to the American College of Radiology (ACR) Appropriateness Criteria, the recommended initial study, Digital Breast Tomosynthesis (DBT), is rated Usually Appropriate.

Who Fits This Clinical Scenario?

This guidance applies specifically to asymptomatic patients who are currently lactating and are due for routine breast cancer screening. These individuals may be of average risk and of an age to begin screening, or they may be at increased risk (e.g., due to personal history, family history, or known genetic mutations like BRCA1/2) and require screening at a younger age. The key element is the absence of new clinical signs or symptoms; this is a surveillance examination, not a diagnostic one.

This workflow should NOT be applied to patients with different clinical presentations, even if they are also lactating. Key exclusion criteria include:

  • A new palpable lump or focal pain: This is a diagnostic scenario, not a screening one. The workup would typically begin with a targeted breast ultrasound, often supplemented with diagnostic mammography.
  • Signs of infection (mastitis or abscess): Patients with breast redness, swelling, and pain require a workup focused on infection and inflammation, for which ultrasound is the primary imaging tool.
  • Nipple discharge (spontaneous, unilateral, bloody/serous): This is another diagnostic indication requiring a dedicated workup, distinct from routine screening.
  • Pregnant patients: While related, breast imaging during pregnancy involves different considerations regarding radiation and physiological changes, and is covered under a separate clinical variant.

Applying a screening workflow to a patient with symptoms can delay the diagnosis of a palpable cancer or other urgent condition.

What Diagnoses Are You Working Up in This Scenario?

The primary goal of screening is the detection of occult, non-palpable breast cancer at its earliest, most treatable stage. During lactation, the breast parenchyma undergoes significant physiologic changes, becoming denser and more vascular. This can make early cancer detection more challenging and can also produce benign findings that mimic malignancy.

The differential diagnosis in this screening context is narrow but critical. The main objective is to distinguish normal, dense lactating tissue from a developing malignancy. While not a true differential in the diagnostic sense, radiologists are actively looking for subtle architectural distortion, suspicious microcalcifications, or an asymmetric density that could represent ductal carcinoma in situ (DCIS) or early-invasive carcinoma.

Additionally, several benign lactation-related changes can be encountered. A galactocele, a milk-filled cyst caused by a blocked duct, can appear as a mass on mammography. Lactating adenomas are benign solid tumors that can grow rapidly under hormonal stimulation. While benign, these entities can sometimes present imaging features that overlap with malignancy, necessitating further workup to confirm their nature. The screening examination serves as the first filter to identify any finding that deviates from the expected pattern of lactating breast tissue.

Why Is Digital Breast Tomosynthesis Screening the Recommended Study for This Presentation?

The ACR rates Digital Breast Tomosynthesis (DBT) as Usually Appropriate for breast cancer screening during lactation. This recommendation is based on DBT’s ability to mitigate the primary challenge of imaging the lactating breast: increased parenchymal density.

DBT, also known as 3D mammography, acquires multiple low-dose images of the breast from different angles, which are then reconstructed into thin, one-millimeter slices. This technique significantly reduces the effect of overlapping tissue, a common issue with standard 2D mammography in dense breasts. For a lactating patient, whose glandular tissue is active and dense, this is particularly advantageous. It improves the radiologist’s ability to detect subtle lesions like spiculated masses and architectural distortion that might otherwise be obscured. This leads to higher cancer detection rates and fewer false positives, reducing the need for unnecessary patient recalls and additional imaging.

Let’s review the ACR ratings for other modalities in this specific scenario:

  • Mammography screening (2D): Also rated Usually Appropriate. It remains a valid screening tool, though it is often performed in conjunction with tomosynthesis where available. The radiation dose is very low (☢☢ 0.1-1mSv), and the risk is considered negligible.
  • US breast: Rated May be appropriate. Ultrasound is not recommended as a primary whole-breast screening tool because it is highly operator-dependent, time-consuming for screening the entire breast volume, and has not been shown to have the same mortality benefit as mammography. Its strength lies in targeted evaluation of a palpable lump or a mammographic finding.
  • MRI breast without and with IV contrast: Rated Usually not appropriate for routine screening in this context. The lactating breast exhibits intense background parenchymal enhancement due to increased vascularity. This can significantly lower the specificity of MRI, leading to a high rate of false-positive findings. While MRI is a key screening tool for certain high-risk populations, its utility is diminished by these physiologic changes during lactation.

A crucial practical pearl for ordering physicians is to instruct the patient to breastfeed or pump as completely as possible from both breasts immediately before her appointment. This temporarily decreases breast density, reduces discomfort from compression, and can substantially improve the quality and interpretability of the images. For detailed technical parameters on image acquisition, see our comprehensive guide on the Screening Mammography (with DBT) protocol.

What’s Next After Digital Breast Tomosynthesis Screening? Downstream Workflow

The results of the screening DBT, reported using the Breast Imaging Reporting and Data System (BI-RADS) classification, will dictate the next steps in the clinical workflow.

  • Negative or Benign Finding (BI-RADS 1 or 2): If the examination is negative or shows clearly benign findings (e.g., a simple cyst or stable fibroadenoma), the patient should be advised to continue breastfeeding as desired and return to her routine screening schedule. No further immediate action is needed.
  • Incomplete Assessment (BI-RADS 0): This is a common outcome in lactating women due to the high breast density. It means the radiologist has identified a potential finding but requires more information. The patient will be called back for diagnostic imaging, which typically includes spot compression mammographic views and/or a targeted breast ultrasound to characterize the area of concern. This is not an abnormal result, but rather a necessary next step for a complete evaluation.
  • Probably Benign Finding (BI-RADS 3): This category is used for findings with a very low (≤2%) likelihood of malignancy. The standard recommendation is a short-interval (e.g., 6-month) follow-up examination. This approach may be used more cautiously in lactating women, as the breast tissue is actively changing. The decision for follow-up versus immediate biopsy is often made in consultation with a breast imaging specialist.
  • Suspicious or Highly Suggestive of Malignancy (BI-RADS 4 or 5): If the screening DBT reveals a suspicious finding, the definitive next step is a biopsy for pathologic diagnosis. In most cases, this will be an ultrasound-guided core needle biopsy, which is safe to perform during lactation.

Pitfalls to Avoid (and When to Get Help)

Navigating breast screening during lactation requires awareness of several potential pitfalls to ensure timely and accurate care.

1. Postponing Screening Unnecessarily: A common pitfall is advising a patient, particularly one at high risk, to delay her screening until she has weaned. The radiation dose from mammography is low and poses no risk to the infant or the milk supply. Delaying screening can mean missing the window for detecting an early-stage cancer.
2. Suboptimal Patient Preparation: Failing to instruct the patient to empty her breasts immediately before the mammogram can lead to technically limited images. The resulting density may obscure a real finding or lead to a BI-RADS 0 assessment, requiring the patient to return for additional imaging that might have been avoided.
3. Misinterpreting Benign Lactation-Related Findings: Clinicians and patients may become anxious about new lumps that are often benign galactoceles. While all new lumps warrant evaluation, it’s important to understand the high prevalence of benign findings in this population.
4. Using MRI as a First-Line Screening Tool: Ordering a screening breast MRI in a lactating patient without a very specific high-risk indication is generally a pitfall due to the high likelihood of false-positive results from background enhancement.

If a screening study results in a BI-RADS 0, 3, 4, or 5 assessment, the patient’s care should be escalated to a breast imaging specialist or a multidisciplinary breast center for management.

Related ACR Topics and Tools

For a comprehensive overview of all clinical scenarios related to breast imaging in this patient population, please consult our parent guide. Additional GigHz tools can help you navigate adjacent clinical questions and inform patient conversations.

Frequently Asked Questions

Is it safe to have a mammogram while I am breastfeeding?

Yes, it is considered safe. The radiation dose from a screening mammogram, including digital breast tomosynthesis (DBT), is very low and focused only on the breast. The radiation does not affect the safety or nutritional quality of your breast milk.

Do I need to ‘pump and dump’ my breast milk after a mammogram?

No. There is no medical reason to discard your breast milk after a mammogram. The radiation used does not remain in your body or enter your milk supply. You can safely breastfeed your baby immediately after the procedure.

Will breastfeeding make my mammogram less accurate?

Lactation increases breast density, which can make interpreting a mammogram more challenging. However, modern techniques like digital breast tomosynthesis (DBT or 3D mammography) are very effective at imaging dense breasts and significantly improve accuracy. Pumping or nursing right before your exam also helps by reducing density.

What if I am called back for more pictures after my screening mammogram?

Being called back for additional imaging (a ‘callback’ or BI-RADS 0 result) is relatively common for lactating women due to high breast density. It does not mean you have cancer. It simply means the radiologist needs more detailed pictures, usually with spot compression views or a targeted ultrasound, to get a clearer look at a specific area.

Should I wait until I’m done breastfeeding to get my screening mammogram?

For most women, especially those at high risk for breast cancer, it is not recommended to postpone a medically necessary screening. The benefits of early detection generally outweigh the minor challenges of imaging during lactation. You should discuss your specific risk factors and the best timing with your healthcare provider.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026